Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Murrell

Showing results (371-380 of 491) with videos related to

Pageof 50
Sort By:
Orphanet Journal of Rare Diseases|June 25, 2020
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)Amy S Paller, John Browning, Milos Nikolic, et al.
Acta Dermato-Venereologica|September 10, 2008
Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literatureNingning Dang, Sandra Klingberg, Adam I Rubin, et al.
The Journal of Dermatological Treatment|April 15, 2014
Age and etiology of childhood epidermolysis bullosa mortalityKam Lun Ellis Hon, Joshua J Li, Bernadette L Cheng, et al.
The Journal of Investigative Dermatology|May 1, 1993
Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domainW R Gammon, D F Murrell, M W Jenison, et al.
Orphanet Journal of Rare Diseases|January 5, 2020
The challenges of living with and managing epidermolysis bullosa: insights from patients and caregiversAnna L Bruckner, Michael Losow, Jayson Wisk, et al.
The British Journal of Dermatology|February 13, 2013
Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinomaM Kim, M Li, L R A Intong, et al.
The British Journal of Dermatology|February 19, 2010
Phenotypic variability associated with WNT10A nonsense mutationsM Van Geel, M Gattas, Y Kesler, et al.
Expert Opinion on Biological Therapy|January 7, 2022
Biological medication in atopic dermatitisRegina Fölster-Holst, Antonio Torrelo, Kinnor Das, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patientsC Y Zhao, J W Frew, J Muhaidat, et al.
Archives of Disease in Childhood|June 27, 2006
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in childrenT Hofman, N Cranswick, P Kuna, et al.
Pageof 50

Showing results (371-380 of 491) with videos related to

Sort By:
Pageof 50
Orphanet Journal of Rare Diseases|June 25, 2020
Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)Amy S Paller, John Browning, Milos Nikolic, et al.
Acta Dermato-Venereologica|September 10, 2008
Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literatureNingning Dang, Sandra Klingberg, Adam I Rubin, et al.
The Journal of Dermatological Treatment|April 15, 2014
Age and etiology of childhood epidermolysis bullosa mortalityKam Lun Ellis Hon, Joshua J Li, Bernadette L Cheng, et al.
The Journal of Investigative Dermatology|May 1, 1993
Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domainW R Gammon, D F Murrell, M W Jenison, et al.
Orphanet Journal of Rare Diseases|January 5, 2020
The challenges of living with and managing epidermolysis bullosa: insights from patients and caregiversAnna L Bruckner, Michael Losow, Jayson Wisk, et al.
The British Journal of Dermatology|February 13, 2013
Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinomaM Kim, M Li, L R A Intong, et al.
The British Journal of Dermatology|February 19, 2010
Phenotypic variability associated with WNT10A nonsense mutationsM Van Geel, M Gattas, Y Kesler, et al.
Expert Opinion on Biological Therapy|January 7, 2022
Biological medication in atopic dermatitisRegina Fölster-Holst, Antonio Torrelo, Kinnor Das, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 18, 2015
Chlorophyll-induced pseudoporphyria with ongoing photosensitivity after cessation - a case series of four patientsC Y Zhao, J W Frew, J Muhaidat, et al.
Archives of Disease in Childhood|June 27, 2006
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in childrenT Hofman, N Cranswick, P Kuna, et al.
Pageof 50